These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 22641659)

  • 1. Combining cetuximab with killer lymphocytes synergistically inhibits human cholangiocarcinoma cells in vitro.
    Morisaki T; Umebayashi M; Kiyota A; Koya N; Tanaka H; Onishi H; Katano M
    Anticancer Res; 2012 Jun; 32(6):2249-56. PubMed ID: 22641659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunomodulation of inducible co-stimulator (ICOS) in human cytokine-induced killer cells against cholangiocarcinoma through ICOS/ICOS ligand interaction.
    He M; Wang Y; Shi WJ; Wang SJ; Sha HF; Feng JX; Wang J
    J Dig Dis; 2011 Oct; 12(5):393-400. PubMed ID: 21955433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines.
    Roda JM; Joshi T; Butchar JP; McAlees JW; Lehman A; Tridandapani S; Carson WE
    Clin Cancer Res; 2007 Nov; 13(21):6419-28. PubMed ID: 17962339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic cytotoxicity and apoptosis induced in human cholangiocarcinoma cell lines by a combined treatment with tumor necrosis factor-alpha (TNF-alpha) and triptolide.
    Panichakul T; Wanun T; Reutrakul V; Sirisinha S
    Asian Pac J Allergy Immunol; 2002 Sep; 20(3):167-73. PubMed ID: 12587840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model.
    Reusch U; Sundaram M; Davol PA; Olson SD; Davis JB; Demel K; Nissim J; Rathore R; Liu PY; Lum LG
    Clin Cancer Res; 2006 Jan; 12(1):183-90. PubMed ID: 16397041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human cytokine-induced killer cells specifically infiltrated and retarded the growth of the inoculated human cholangiocarcinoma cells in SCID mice.
    Wongkajornsilp A; Somchitprasert T; Butraporn R; Wamanuttajinda V; Kasetsinsombat K; Huabprasert S; Maneechotesuwan K; Hongeng S
    Cancer Invest; 2009 Feb; 27(2):140-8. PubMed ID: 19235585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the anti-epidermal growth factor receptor antibody cetuximab on cholangiocarcinoma of the liver.
    Huang TW; Wang CH; Hsieh CB
    Onkologie; 2007 Mar; 30(3):129-31. PubMed ID: 17341899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NKG2D-directed cytokine-activated killer lymphocyte therapy combined with gemcitabine for patients with chemoresistant metastatic solid tumors.
    Morisaki T; Hirano T; Koya N; Kiyota A; Tanaka H; Umebayashi M; Onishi H; Katano M
    Anticancer Res; 2014 Aug; 34(8):4529-38. PubMed ID: 25075096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholangiocarcinoma-derived exosomes inhibit the antitumor activity of cytokine-induced killer cells by down-regulating the secretion of tumor necrosis factor-α and perforin.
    Chen JH; Xiang JY; Ding GP; Cao LP
    J Zhejiang Univ Sci B; 2016 Jul; 17(7):537-44. PubMed ID: 27381730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The case of a patient with peritoneal metastasis from cholangiocarcinoma who responded to adoptive immunotherapy and cetuximab].
    Kan N; Yoshikawa K; Matsushita N; Fujii T
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):1759-61. PubMed ID: 24393913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MUC1-specific targeting immunotherapy with bispecific antibodies: inhibition of xenografted human bile duct carcinoma growth.
    Katayose Y; Kudo T; Suzuki M; Shinoda M; Saijyo S; Sakurai N; Saeki H; Fukuhara K; Imai K; Matsuno S
    Cancer Res; 1996 Sep; 56(18):4205-12. PubMed ID: 8797593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclins D1, E, A expression and synergistic cytotoxicity to a cholangiocarcinoma cell line from recombinant TNF-alpha and PHA supernate.
    Vongsakul M; Aksomboon A
    Asian Pac J Allergy Immunol; 2002 Mar; 20(1):57-60. PubMed ID: 12125919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. L1 cell adhesion molecule is a novel therapeutic target in intrahepatic cholangiocarcinoma.
    Min JK; Kim JM; Li S; Lee JW; Yoon H; Ryu CJ; Jeon SH; Lee JH; Kim JY; Yoon HK; Lee YK; Kim BH; Son YS; Choi HS; Lim NK; Kim DG; Hong HJ
    Clin Cancer Res; 2010 Jul; 16(14):3571-80. PubMed ID: 20501614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward osteosarcoma.
    Pahl JH; Ruslan SE; Buddingh EP; Santos SJ; Szuhai K; Serra M; Gelderblom H; Hogendoorn PC; Egeler RM; Schilham MW; Lankester AC
    Clin Cancer Res; 2012 Jan; 18(2):432-41. PubMed ID: 22090361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines.
    Kurai J; Chikumi H; Hashimoto K; Yamaguchi K; Yamasaki A; Sako T; Touge H; Makino H; Takata M; Miyata M; Nakamoto M; Burioka N; Shimizu E
    Clin Cancer Res; 2007 Mar; 13(5):1552-61. PubMed ID: 17332301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular chemotherapy combined with radiation therapy enhances killing of cholangiocarcinoma cells in vitro and in vivo.
    Pederson LC; Buchsbaum DJ; Vickers SM; Kancharla SR; Mayo MS; Curiel DT; Stackhouse MA
    Cancer Res; 1997 Oct; 57(19):4325-32. PubMed ID: 9331094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation propagation, and targeting of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus recombinant IL-2. An efficient strategy for adoptive tumor immunotherapy.
    Nishimura T; Nakamura Y; Takeuchi Y; Tokuda Y; Iwasawa M; Kawasaki A; Okumura K; Habu S
    J Immunol; 1992 Jan; 148(1):285-91. PubMed ID: 1345787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study.
    Chan JK; Hamilton CA; Cheung MK; Karimi M; Baker J; Gall JM; Schulz S; Thorne SH; Teng NN; Contag CH; Lum LG; Negrin RS
    Clin Cancer Res; 2006 Mar; 12(6):1859-67. PubMed ID: 16551871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
    Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
    Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo antitumor effects of recombinant bispecific antibodies based on humanized anti-EGFR antibody.
    Watanabe Y; Asano R; Arai K; Shimomura I; Ogata H; Kawaguchi H; Hayashi H; Ohtsuka H; Yoshida H; Katayose Y; Egawa S; Nakanishi T; Umetsu M; Yasui H; Ishida T; Imai K; Kudo T; Unno M; Kumagai I
    Oncol Rep; 2011 Oct; 26(4):949-55. PubMed ID: 21743971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.